Table 1 Characteristics of cases of AML treated during pregnancy at our Istitution

Mother’s age, years

31

Gestational age, weeks

14

Induction chemotherapy

-Induction: daunorubicin 50 mg/m² (days 1, 3, 5) and cytosine arabinoside 3 g/m² (days 1–5)

-Reinduction: fludarabine 30 mg/m² (days 1–4), cytosine arabinoside 2 g/m² (days 1–4) and idarubicin 12 mg/m² (days 1–4)

Consolidation treatment

-Cytosine arabinoside 3 g/m² twice a day (days 1–3-5)

-Myeloablative sibling HSCT (conditioning regimen: busulfan 0,8 mg/kg three times a day days −9 -8 -7 -6 and cyclophosphamide 60 mg/kg days −3 -2)

Maternal outcome

CR

Fetal outcome

Surgical abortion at AML diagnosis

Delivery

-

Mother’s age (years)

36

Gestational age (weeks)

32

Induction chemotherapy

Daunorubicin 50 mg/m² (days 1, 3, 5) and cytosine arabinoside 3 g/m² (days 1–5)

Consolidation treatment

-Cytosine arabinoside 3 g/m² twice a day (days 1–4), daunorubicin 50 mg/m² (days 5–6)

-Cytosine arabinoside 300 mg/m² (days 1–5), daunorubicin 50 mg/m² (days 1–2)

-Cytosine arabinoside 300 mg/m² (days 1–5), etoposide 150 mg/m² (days 1–3)

-Cytosine arabinoside 1 g/m² twice a day (days 1, 3, 5)

-Autologous HSCT (conditioning regimen: cytosine arabinoside 3 g/m² twice a day, cyclophosphamide 60 mg/kg twice a day for two days, 1000 cGy of total body irradiation)

Maternal outcome

Fetal outcome

Delivery

CR

Live birth, normal child

Cesarean at AML diagnosis

Mother’s age (years)

32

Gestational age (weeks)

26

Induction chemotherapy

Cytosine arabinoside 2 g/m² twice a day (days 1, 2, 8, 9) and idarubicin 18 mg/m² (days 2, 3, 10) 6 weeks after delivery when MDS progressed to AML

Consolidation treatment

-Cytosine arabinoside 100 mg/m² (days 1–7), idarubicin 10 mg/m² (days 1–3)

-Myeloablative sibling HSCT (conditioning regimen: busulfan 0.8 mg/kg three times a day, days −9 -8 -7 -6, cyclophosphamide 60 mg/kg, days −3 -2)

Maternal outcome

Fetal outcome

Delivery

CR

Live birth, normal child

Cesarean at 32 + 2 weeks after administration of betamethasone

Mother’s age (years)

34

Gestational age (weeks)

31

Induction chemotherapy

Cytosine arabinoside 3 g/m² (days 1–5) and daunorubicin 50 mg/m² (days 2, 4, 5)

Consolidation treatment

-Cytosine arabinoside 3 g/m² twice a day (days 1–4), daunorubicin 50 mg/m² (days 5–6)

−2 cycles of cytosine arabinoside 3 g/m² twice a day (days 1–3-5)

Maternal outcome

Fetal outcome

Delivery

CR

Intrauterine fetal death

Cesarean at AML diagnosis

Mother’s age (years)

39

Gestational age (weeks)

24 + 5

Induction chemotherapy

Cytosine arabinoside 100 mg/m² (days 1–7) and daunorubicin 40 mg/m² (days 1–3)

Consolidation treatment

4 cycles of cytosine arabinoside 3 g/m² twice a day (days 1–3-5)

Maternal outcome

CR; death for septic shock during the fourth and last consolidation cycle with high dose cytosine arabinoside

Fetal outcome

Delivery

Live birth, normal child

Cesarean at 30 weeks after administration of betamethasone